| Consensus Recommendations for Severe Aplastic Anemia |
|
Blood Advances |
Aplastic Anemia |
| Consensus recommendations for severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
|
Haematologica |
Aplastic Anemia |
| Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
|
Haematologica |
Aplastic Anemia |
| Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy |
|
International Journal of Laboratory Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations |
|
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
|
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
